Literature DB >> 23307144

Interferon regulatory factor 3 is a negative regulator of pathological cardiac hypertrophy.

Jing Lu1, Zhou-Yan Bian, Ran Zhang, Yan Zhang, Chen Liu, Ling Yan, Shu-Min Zhang, Ding-Sheng Jiang, Xiang Wei, Xue Hai Zhu, Manyin Chen, Ai-Bing Wang, Yingjie Chen, Qinglin Yang, Peter P Liu, Hongliang Li.   

Abstract

Interferon regulatory factor (IRF) 3, a member of the highly conserved IRF family transcription factors, plays a pivotal role in innate immune response, apoptosis, and oncogenesis. Recent studies have implicated IRF3 in a wide range of host defense. However, whether IRF3 induces defensive responses to hypertrophic stresses such as biomechanical stress and neurohumoral factors remains unclear. Herein, we employed an IRF3-deficient mouse model, cardiac-specific IRF3-overexpression mouse model and isolated cardiomyocytes to investigate the role of IRF3 in cardiac hypertrophy induced by aortic banding (AB) or isoproterenol (ISO). The extent of cardiac hypertrophy was quantitated by echocardiography as well as by pathological and molecular analysis. Our results demonstrate that IRF3 deficiency profoundly exacerbated cardiac hypertrophy, whereas overexpression of IRF3 in the heart significantly blunted pathological cardiac remodeling induced by pressure overload. Similar results were also observed in cultured cardiomyocytes upon the treatment with ISO. Mechanistically, we discovered that IRF3 interacted with ERK2 and thereby inhibited the ERK1/2 signaling. Furthermore, inactivation of ERK1/2 by U0126 offset the IRF3-deficient-mediated hypertrophic response induced by aortic banding. Altogether, these data demonstrate that IRF3 plays a protective role in AB-induced hypertrophic response by inactivating ERK1/2 in the heart. Therefore, IRF3 could be a new target for the prevention and therapy of cardiac hypertrophy and failure.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23307144     DOI: 10.1007/s00395-012-0326-9

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  27 in total

1.  Regulator of G-protein signalling 5 protects against atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Wen-Lin Cheng; Pi-Xiao Wang; Tao Wang; Yan Zhang; Cheng Du; Hongliang Li; Yong Ji
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

Review 2.  The interferon regulatory factors as novel potential targets in the treatment of cardiovascular diseases.

Authors:  Xiao-Jing Zhang; Ding-Sheng Jiang; Hongliang Li
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

3.  Dickkopf-3 attenuates pressure overload-induced cardiac remodelling.

Authors:  Yan Zhang; Yu Liu; Xue-Hai Zhu; Xiao-Dong Zhang; Ding-Sheng Jiang; Zhou-Yan Bian; Xiao-Fei Zhang; Ke Chen; Xiang Wei; Lu Gao; Li-Hua Zhu; Qinglin Yang; Guo-Chang Fan; Wayne B Lau; Xinliang Ma; Hongliang Li
Journal:  Cardiovasc Res       Date:  2014-01-09       Impact factor: 10.787

4.  Interferon regulatory factor 7 functions as a novel negative regulator of pathological cardiac hypertrophy.

Authors:  Ding-Sheng Jiang; Yu Liu; Heng Zhou; Yan Zhang; Xiao-Dong Zhang; Xiao-Fei Zhang; Ke Chen; Lu Gao; Juan Peng; Hui Gong; Yingjie Chen; Qinglin Yang; Peter P Liu; Guo-Chang Fan; Yunzeng Zou; Hongliang Li
Journal:  Hypertension       Date:  2014-01-06       Impact factor: 10.190

5.  Interferon regulatory factors in heart: stress response beyond inflammation.

Authors:  Haipeng Sun; Yibin Wang
Journal:  Hypertension       Date:  2014-01-06       Impact factor: 10.190

6.  Role of interferon regulatory factor 4 in the regulation of pathological cardiac hypertrophy.

Authors:  Ding-Sheng Jiang; Zhou-Yan Bian; Yan Zhang; Shu-Min Zhang; Yi Liu; Rui Zhang; Yingjie Chen; Qinglin Yang; Xiao-Dong Zhang; Guo-Chang Fan; Hongliang Li
Journal:  Hypertension       Date:  2013-04-15       Impact factor: 10.190

7.  Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice.

Authors:  Xin-An Wang; Ran Zhang; Dingsheng Jiang; Wei Deng; Shumin Zhang; Shan Deng; Jinfeng Zhong; Tao Wang; Li-Hua Zhu; Li Yang; Shufen Hong; Sen Guo; Ke Chen; Xiao-Fei Zhang; Zhigang She; Yingjie Chen; Qinglin Yang; Xiao-Dong Zhang; Hongliang Li
Journal:  Hepatology       Date:  2013-06-25       Impact factor: 17.425

8.  Signal regulatory protein-α protects against cardiac hypertrophy via the disruption of toll-like receptor 4 signaling.

Authors:  Ding-Sheng Jiang; Xiao-Fei Zhang; Lu Gao; Jing Zong; Heng Zhou; Yu Liu; Yan Zhang; Zhou-Yan Bian; Li-Hua Zhu; Guo-Chang Fan; Xiao-Dong Zhang; Hongliang Li
Journal:  Hypertension       Date:  2013-10-07       Impact factor: 10.190

9.  Fibronectin contributes to pathological cardiac hypertrophy but not physiological growth.

Authors:  Mathias H Konstandin; Mirko Völkers; Brett Collins; Pearl Quijada; Mercedes Quintana; Andrea De La Torre; Lucy Ormachea; Shabana Din; Natalie Gude; Haruhiro Toko; Mark A Sussman
Journal:  Basic Res Cardiol       Date:  2013-08-04       Impact factor: 17.165

10.  Interferon regulatory factor 8 modulates phenotypic switching of smooth muscle cells by regulating the activity of myocardin.

Authors:  Shu-Min Zhang; Lu Gao; Xiao-Fei Zhang; Ran Zhang; Li-Hua Zhu; Pi-Xiao Wang; Song Tian; Da Yang; Ke Chen; Ling Huang; Xiao-Dong Zhang; Hongliang Li
Journal:  Mol Cell Biol       Date:  2013-11-18       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.